Tyrosine kinase inhibitors: Their on-target toxicities as potential indicators of efficacy

Drug Safety

Volumn 36, Issue 6, 2013, Pages 413-426

  Shah, Devron R ^a   Shah, Rashmi R ^a   Morganroth, Joel ^b  

^a Rashmi Shah Consultancy Ltd   (United Kingdom)

^b eResearchTechnology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AXITINIB; BOSUTINIB; CRIZOTINIB; DASATINIB; ERLOTINIB; GEFITINIB; IMATINIB; LAPATINIB; NILOTINIB; NITRIC OXIDE; PAZOPANIB; PROTEIN TYROSINE KINASE INHIBITOR; REGORAFENIB; RUXOLITINIB; SORAFENIB; SUNITINIB; THYROTROPIN; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR INHIBITOR; VEMURAFENIB;

ANGIOGENESIS; ARTERY THROMBOSIS; BLEEDING; BONE MARROW SUPPRESSION; CANCER PATIENT; CARCINOGENESIS; CLINICAL ASSESSMENT; CLINICAL TRIAL (TOPIC); CONGESTIVE HEART FAILURE; DIGESTIVE SYSTEM PERFORATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; EDEMA; EFFUSION; ENZYME INHIBITION; EVIDENCE BASED MEDICINE; FOOD AND DRUG ADMINISTRATION; HEART LEFT VENTRICLE FAILURE; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; HYPOTHYROIDISM; KIDNEY CARCINOMA; KIDNEY FAILURE; LIVER TOXICITY; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; NEOPLASM; NEUROPATHY; OVERALL SURVIVAL; PHARMACODYNAMICS; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PULMONARY HYPERTENSION; QT PROLONGATION; REVIEW; RISK BENEFIT ANALYSIS; THYROTROPIN BLOOD LEVEL; VASCULAR ENDOTHELIUM; VEIN THROMBOSIS;

ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; EVIDENCE-BASED MEDICINE; HUMANS; NEOPLASM PROTEINS; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RISK ASSESSMENT; SKIN;

EID: 84877773278     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-013-0050-x     Document Type: Review

References (113)

1. Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med. 2005;353(2):172-87.
2. Chen MH, Kerkela R, Force T. Mechanisms of cardiomyopathy associated with tyrosine kinase inhibitor cancer therapeutics. Circulation. 2008;118(1):84-95.
3. Shah RR, Morganroth J, Shah DR. Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarization (QT interval). Drug Saf. doi: 10.1007/s40264-013-0047-5
4. Keefe D, Bowen J, Gibson R, et al. Noncardiac vascular toxicities of vascular endothelial growth factor inhibitors in advanced cancer: a review. Oncologist. 2011;16(4):432-44.
5. Cook KM, Figg WD. Angiogenesis inhibitors: current strategies and future prospects. CA Cancer J Clin. 2010;60(4):222-43.
6. Gotlink KJ, Verheul HMW. Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action? Angiogenesis. 2010;13(1):1-14.
7. Laurent-Puig P, Lievre A, Blons H. Mutations and response to epidermal growth factor receptor inhibitors. Clin Cancer Res. 2009;15(4):1133-9.
8. Elice F, Rodeghiero F, Falanga A, et al. Thrombosis associated with angiogenesis inhibitors. Best Pract Res Clin Haematol. 2009;22(1):115-28.
9. Sonpavde G, Bellmunt J, Schutz F, et al. The double edged sword of bleeding and clotting from VEGF inhibition in renal cancer patients. Curr Oncol Rep. 2012;14(4):295-306.
10. Amir E, Seruga B, Martinez-Lopez J, et al. Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs. J Clin Oncol. 2011;29(18):2543-9.
11. van Cruijsen H, van der Veldt A, Hoekman K. Tyrosine kinase inhibitors of VEGF receptors: clinical issues and remaining questions. Front Biosci. 2009;14(1):2248-68.
12. Roodhart JM, Langenberg MH, Witteveen E, et al. The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway. Curr Clin Pharmacol. 2008;3(2):132-43.
13. Eaby B, Culkin A, Lacouture ME. An interdisciplinary consensus on managing skin reactions associated with human epidermal growth factor receptor inhibitors. Clin J Oncol Nurs. 2008;12(2):283-90.
14. Asnacios A, Naveau S, Perlemuter G. Gastrointestinal toxicities of novel agents in cancer therapy. Eur J Cancer. 2009;45(Suppl. 1):332-42.
15. Steeghs N, Gelderblom H, Roodt JO, et al. Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor. Clin Cancer Res. 2008;14(11):3470-6.
16. GlaxoSmilthKline. Clinical Study Register. A meta-analysis of the cumulative incidence of hypertension in the first month of treatment with pazopanib across three RCC studies: VEG102616, VEG105192 and VEG107769 (Study number 115227). Available from URL: http://www.gsk-clinicalstudyregister.com/ result-detail.jsp?protocolId=115227&studyId=7FE7FADD-D3FA-4BD6-9BF5- 0845FF2A2C90&compound=pazopanib&type=Compound&letterrange=L-P. Accessed 25 Oct 2012.
17. FDA. Label for INLYTA (axitinib) approved on 27 January 2012. Available from URL: http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/202324lbl. pdf. Accessed 7 Oct 2012.
18. FDA. Label for BOSULIF (bosutinib) approved on 4 September 2012. Available from URL: http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/ 203341lbl.pdf. Accessed 7 Oct 2012.
19. FDA. Label for XALKORI (crizotinib) approved on 24 February 2012. Available from URL: http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/ 202570s003lbl.pdf. Accessed 7 Oct 2012.
20. FDA. Label for SPRYCEL (dasatinib) approved on 7 October 2011. Available from URL: http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/ 021986s009s010lbl.pdf. Accessed 7 Oct 2012.
21. FDA. Label for TARCEVA (erlotinib) approved on 17 April 2012. Available from URL: http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/ 021743s017lbl.pdf. Accessed 7 Oct 2012.
22. FDA. Label for IRESSA (gefitinib) approved on 17 June 2005. Available from URL: http://www.accessdata.fda.gov/drugsatfda-docs/label/2005/ 021399s008lbl.pdf. Accessed 7 Oct 2012.
23. FDA. Label for GLEEVEC (imatinib) approved on 31 January 2012. Available from URL: http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/ 021588s035lbl.pdf. Accessed 7 Oct 2012.
24. FDA. Label for TYKERB (lapatinib) approved on 14 February 2012. Available from URL: http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/ 022059s013lbl.pdf. Accessed 7 Oct 2012.
25. FDA. Label for TASIGNA (nilotinib) approved on 1 May 2012. Available from URL: http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/022068s012lbl. pdf. Accessed 7 Oct 2012.
26. FDA. Label for VOTRIENT (pazopanib) approved on 26 April 2012. Available from URL: http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/022465s-010S- 012lbl.pdf. Accessed 7 Oct 2012.
27. FDA. Label for STIVARGA (regorafenib) approved on 27 September 2012. Available from URL: http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/ 203085lbl.pdf. Accessed 7 Oct 2012.
28. FDA. Label for JAKAFI (ruxolitinib) approved on 21 June 2012. Available from URL: http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/ 202192s001lbl.pdf. Accessed 7 Oct 2012.
29. FDA. Label for NEXAVAR (sorafenib) approved on 14 October 2011. Available from URL: http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/ 021923s012lbl.pdf. Accessed 7 Oct 2012.
30. Label for SUTENT (sunitinib) approved on 20 April 2012. Available from URL: http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/021938s019s020lbl. pdf. Accessed 7 Oct 2012.
31. FDA. Label for CAPRELSA (vandetanib) approved on 22 June 2011. Available from URL: http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/ 022405s001lbl.pdf. Accessed 7 Oct 2012.
32. FDA. Label for ZELBORAF (vemurafenib) approved on 17 August 2011. Available from URL: http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/ 202429s000lbl.pdf. Accessed 7 Oct 2012.
33. Nazer B, Humphreys BD, Moslehi J. Effects of novel angiogenesis inhibitors for the treatment of cancer on the cardiovascular system: focus on hypertension. Circulation. 2011;124(15):1687-91.
34. Qi WX, Shen Z, Lin F, et al. Incidence and risk of hypertension with vandetanib in cancer patients: a systematic review and meta-analysis of clinical trials. Br J Clin Pharmacol. 2013;75(4):919-30.
35. Rini BI, Cohen DP, Lu DR, et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst. 2011;103(9):763-73.
36. George S, Reichardt P, Lechner T, et al. Hypertension as a potential biomarker of efficacy in patients with gastrointestinal stromal tumor treated with sunitinib. Ann Oncol. 2012;23(12):3180-7.
37. Rini BI, Schiller JH, Fruehauf JP, et al. Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors. Clin Cancer Res. 2011;17(11):3841-9.
38. Estfan B, Byrne M, Kim R. Sorafenib in advanced hepatocellular carcinoma: hypertension as a potential surrogate marker for efficacy. Am J Clin Oncol (Epub 2012 Apr 27).
39. Kim JJ, Vaziri SA, Rini BI, et al. Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib. Cancer. 2012;118(7):1946-54.
40. Li XS, Wu X, Zhao PJ, et al. Efficacy and safety of sunitinib in the treatment of metastatic renal cell carcinoma. Chin Med J (Engl). 2011;124(18):2920-4.
41. Clemons J, Gao D, Naam M, et al. Thyroid dysfunction in patients treated with sunitinib or sorafenib. Clin Genitourin Cancer. 2012;10(4):225-31.
42. Daimon M, Kato T, Kaino W, et al. Thyroid dysfunction in patients treated with tyrosine kinase inhibitors, sunitinib, sorafenib and axitinib, for metastatic renal cell carcinoma. Jpn J Clin Oncol. 2012;42(8):742-7.
43. Torino F, Corsello SM, Longo R, et al. Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy. Nat Rev Clin Oncol. 2009;6(4):219-28.
44. Sakurai K, Fukazawa H, Arihara Z, et al. Sunitinib-induced thyrotoxicosis followed by persistent hypothyroidism with shrinkage of thyroid volume. Tohoku J Exp Med. 2010;222(1):39-44.
45. Krouse RS, Royal RE, Heywood G, et al. Thyroid dysfunction in 281 patients with metastatic melanoma or renal carcinoma treated with interleukin-2 alone. J Immunother Emphasis Tumor Immunol. 1995;18(4):272-8.
46. Schwartzentruber DJ, White DE, Zweig MH, et al. Thyroid dysfunction associated with immunotherapy for patients with cancer. Cancer. 1991;68(11):2384-90.
47. Wong E, Rosen LS, Mulay M, et al. Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity. Thyroid. 2007;17(4):351-5.
48. Mannavola D, Coco P, Vannucchi G, et al. A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake. J Clin Endocrinol Metab. 2007;92(9):3531-4.
49. Abdulrahman RM, Verloop H, Hoftijzer H, et al. Sorafenib-induced hypothyroidism is associated with increased type 3 deiodination. J Clin Endocrinol Metab. 2010;95(8):3758-62.
50. Kappers MH, van Esch JH, Smedts FM, et al. Sunitinib-induced hypothyroidism is due to induction of type 3 deiodinase activity and thyroidal capillary regression. J Clin Endocrinol Metab. 2011;96(10):3087-94.
51. Vesely D, Astil J, Lastuvka P, et al. Serum levels of IGF-I, HGF, TGFβ1, bFGF and VEGF in thyroid gland tumors. Physiol Res. 2004;53(1):83-9.
52. Makita N, Miyakawa M, Fujita T, et al. Sunitinib induces hypothyroidism with a markedly reduced vascularity. Thyroid. 2010;20(3):323-6.
53. Sato S, Muraishi K, Tani J, et al. Clinical characteristics of thyroid abnormalities induced by sunitinib treatment in Japanese patients with renal cell carcinoma. Endocr J. 2010;57(10):873-80.
54. Kitajima K, Takahashi S, Maeda T, et al. Thyroid size change by CT monitoring after sorafenib or sunitinib treatment in patients with renal cell carcinoma: comparison with thyroid function. Eur J Radiol. 2012;81(9):2060-5.
55. Riesenbeck LM, Bierer S, Hoffmeister I, et al. Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib. World J Urol. 2011;29(6):807-13.
56. Schmidinger M, Vogl UM, Bojic M, et al. Hypothyroidism in patients with renal cell carcinoma: blessing or curse? Cancer. 2011;117(3):534-44.
57. Robinson ES, Matulonis UA, Ivy P, et al. Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor. Clin J Am Soc Nephrol. 2010;5(3):477-83.
58. Eskens FA, de Jonge MJ, Bhargava P, et al. Biologic and clinical activity of tivozanib (AV-951, KRN-951), a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine kinases, in a 4-week-on, 2-week-off schedule in patients with advanced solid tumors. Clin Cancer Res. 2011;17(22):7156-63.
59. Eremina V, Jefferson JA, Kowalewska J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med. 2008;358(11):1129-36.
60. Eremina V, Quaggin SE. Biology of anti-angiogenc therapy-induced thrombotic microangiopathy. Semin Nephrol. 2010;30(6):582-90.
61. Izzedine H, Massard C, Spano JP, et al. VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management. Eur J Cancer. 2010;46(2):439-48.
62. Hattori S, Kanda S, Harita Y. Tyrosine kinase signalling in kidney glomerular podocytes. J Signal Transduct. 2011;2011:317852. doi: 10.1155/2011/317852.
63. Bertuccio C, Veron D, Aggarwal PK, et al. Vascular endothelial growth factor receptor 2 direct interaction with nephrin links VEGF-A signals to actin in kidney podocytes. J Biol Chem. 2011;286(46):39933-44.
64. Sugimoto H, Hamano Y, Charytan D, et al. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem. 2003;278(15):12605-8.
65. Blanco S, Bonet J, López D, et al. ACE inhibitors improve nephrin expression in Zucker rats with glomerulosclerosis. Kidney Int Suppl. 2005;67(S93):S10-4.
66. Agabiti-Rosei E. Structural and functional changes of the microcirculation in hypertension: influence of pharmacological therapy. Drugs. 2003;63(Spec No 1):19-29.
67. Rosen AC, Wu S, Damse A, et al. Risk of rash in cancer patients treated with vandetanib: systematic review and meta-analysis. J Clin Endocrinol Metab. 2012;97(4):1125-33.
68. Lacouture ME, Laabs SM, Koehler M, et al. Analysis of dermatologic events in patients with cancer treated with lapatinib. Breast Cancer Res Treat. 2009;114(3):485-93.
69. Choi NM. Chemotherapy-induced iatrogenic injury of skin: new drugs and new concepts Clin Dermatol. 2011;29(6):587-601.
70. Hirsh V. Managing treatment-related adverse events associated with EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer. Curr Oncol. 2011;18(3):126-38.
71. Suzumura T, Kimura T, Kudoh S, et al. Reduced CYP2D6 function is associated with gefitinib-induced rash in patients with non-small cell lung cancer. BMC Cancer. 2012;4(12):568.
72. Li J, Karlsson MO, Brahmer J, et al. CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors. J Natl Cancer Inst. 2006;98(23):1714-23.
73. Pérez-Soler R, Zou Y, Li T, et al. The phosphatase inhibitor menadione (vitamin K3) protects cells from EGFR inhibition by erlotinib and cetuximab. Clin Cancer Res. 2011;17(21):6766-77.
74. Mitra SS, Simcock R. Erlotinib induced skin rash spares skin in previous radiotherapy field. J Clin Oncol. 2006;24(16):e28-9.
75. Pérez-Soler R. Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome? Oncology (Williston Park). 2003;17(11 Suppl. 12):23-8.
76. Pérez-Soler R. Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer. Clin Lung Cancer. 2006;8(Suppl. 1):S7-14.
77. Wacker B, Nagrani T, Weinberg J, et al. Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res. 2007;13(13):3913-21.
78. Liu G, Gurubhagavatula S, Zhou W, et al. Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib. Pharmacogenomics J. 2008;8(2):129-38.
79. Vincenzi B, Santini D, Russo A, et al. Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib. Oncologist. 2010;15(1):85-92.
80. Petrelli F, Borgonovo K, Cabiddu M, et al. Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: a literature-based meta-analysis of 24 trials. Lung Cancer. 2012;78(1):8-15.
81. Stepanski EJ, Reyes C, Walker MS, et al. The association of rash severity with overall survival: findings from patients receiving erlotinib for pancreatic cancer in the community setting. Pancreas. 2013;42(1):32-6.
82. Fiala O, Pesek M, Finek J, et al. Skin rash as useful marker of erlotinib efficacy in NSCLC and its impact on clinical practice. Neoplasma. 2013;60(1):26-32.
83. Mita AC, Papadopoulos K, de Jonge MJA, et al. Erlotinib 'dosing-to-rash': a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer. Br J Cancer. 2011;105(7):938-44.
84. Liu HB, Wu Y, Lv TF, et al. Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysis. PLoS One. 2013;8(1):e55128.
85. Jonker DJ, O'Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med. 2007;357(20):2040-8.
86. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359(17):1757-65.
87. Van Cutsem E, Tejpar S, Vanbeckevoort D, et al. Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study. J Clin Oncol. 2012;30(23):2861-8.
88. Lièvre A, Bachet JB, Boige V, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol. 2008;26(3):374-9.
89. FDA. Oncologic Drugs Advisory Committee meeting (24 September 2002). Clinical review: IRESSA NDA 21-399. Available from URL: http://www.fda.gov/ ohrms/dockets/ac/02/briefing/3894B1-03-FDA-Medical%20Officer%20Review.pdf. Accessed 22 Oct 2012.
90. European Medicines Agency. NEXAVAR public assessment report (4 March 2007). Available from URL: http://www.emea.europa.eu/docs/en-GB/document- library/EPAR-Scientific-Discussion/human/000690/WC500027707.pdf. Accessed 22 Oct 2012.
91. European Medicines Agency. VOTRIENT public assessment report (EMA/CHMP/248579/2010) [14 June 2010]. Available from URL: http://www.emea. europa.eu/docs/en-GB/document-library/EPAR-Public-assessment-report/human/ 001141/WC500094275.pdf. Accessed 22 Oct 2012.
92. Marshall JL. Maximum-tolerated dose, optimum biologic dose, or optimum clinical value: dosing determination of cancer therapies. J Clin Oncol. 2012;30(23):2815-6.
93. Mukohara T, Nakajima H, Mukai H, et al. Effect of axitinib (AG-013736) on fatigue, thyroid-stimulating hormone, and biomarkers: a phase I study in Japanese patients. Cancer Sci. 2010;101(4):963-8.
94. Fujiwara Y, Kiyota N, Chayahara N, et al. Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients. Invest New Drugs. 2012;30(3):1055-64.
95. European Medicines Agency. IRESSA public assessment report (EMEA/CHMP/563746/2008) [22 July 2009]. Available from URL:0 http://www.emea.europa.eu/docs/en-GB/document-library/EPAR-Public-assessment- report/human/001016/WC500036361.pdf. Accessed 22 Oct 2012.
96. FDA. Clinical pharmacology and biopharmaceutics review(s) - INLYTA NDA. Application number 203324Orig1s000. Available from URL: http://www.accessdata. fda.gov/drugsatfda-docs/nda/2012/202324Orig1s000ClinPharmR.pdf. Accessed 22 Oct 2012.
97. Girardi F, Franceschi E, Brandes AA. Cardiovascular safety of VEGF-targeting therapies: current evidence and handling strategies. Oncologist. 2010;15(7):683-94.
98. Franklin PH, Banfor PN, Tapang P, et al. Effect of the multitargeted receptor tyrosine kinase inhibitor, ABT-869 [N-(4-(3-amino-1H-indazol-4-yl) phenyl)-N'-(2-fluoro-5-methylphenyl)urea], on blood pressure in conscious rats and mice: reversal with antihypertensive agents and effect on tumor growth inhibition. J Pharmacol Exp Ther. 2009;329(3):928-37.
99. Izzedine H, Ederhy S, Goldwasser F, et al. Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol. 2009;20(5):807-15.
100. Molteni A, Heffelfinger S, Moulder JE, et al. Potential deployment of angiotensin I converting enzyme inhibitors and of angiotensin II type 1 and type 2 receptor blockers in cancer chemotherapy. Anticancer Agents Med Chem. 2006;6(5):451-60.
101. Wolter P, Stefan C, Decallonne B, et al. The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation. Br J Cancer. 2008;99(3):448-54.
102. Garfield DH, Wolter P, Schöffski P, et al. Documentation of thyroid function in clinical studies with sunitinib: why does it matter? J Clin Oncol. 2008;26(31):5131-2.
103. Lynch TJ Jr, Kim ES, Eaby B, et al. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist. 2007;12(5):610-21.
104. Thatcher N, Nicolson M, Groves RW, for the UK Erlotinib Skin Toxicity Management Consensus Group, et al. Expert consensus on the management of erlotinib-associated cutaneous toxicity in the UK. Oncologist. 2009;14(8):840-7.
105. Potthoff K, Hofheinz R, Hassel JC, et al. Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion. Ann Oncol. 2011;22(3):524-35.
106. Abdullah SE, Haigentz M Jr, Piperdi B. Dermatologic toxicities from monoclonal antibodies and tyrosine kinase inhibitors against EGFR: pathophysiology and management. Chemother Res Pract. 2012;2012:351210.
107. Robert C, Sibaud V, Mateus C, et al. Advances in the management of cutaneous toxicities of targeted therapies. Semin Oncol. 2012;39(2):227-40.
108. Hassel JC, Kripp M, Al-Batran S, et al. Treatment of epidermal growth factor receptor antagonist-induced skin rash: results of a survey among German oncologists. Onkologie. 2010;33(3):94-8.
109. Bidoli P, Cortinovis DL, Colombo I, et al. Isotretinoin plus clindamycin seem highly effective against severe erlotinib-induced skin rash in advanced non-small cell lung cancer. J Thorac Oncol. 2010;5(10):1662-3.
110. Requena C, Llombart B, Sanmartín O. Acneiform eruptions induced by epidermal growth factor receptor inhibitors: treatment with oral isotretinoin. Cutis. 2012;90(2):77-80.
111. Blanchetot C, Tertoolen LG, den Hertog J. Regulation of receptor protein-tyrosine phosphatase alpha by oxidative stress. EMBO J. 2002;21(4):493-503.
112. Talon Therapeutics, Inc. Safety, tolerability and systemic absorption of menadione topical lotion for epidermal-growth-factor-receptor (EGFR) inhibitor-associated rash [ClinicalTrials.gov identifier NCT00656786]. US National Institutes of Health, ClinicalTrials.gov. Available from URL: http://www.clinicaltrials.gov. Accessed 29 Oct 2012.
113. Mayo Clinic. Menadione topical lotion in treating skin discomfort and psychological distress in patients with cancer receiving panitumumab, erlotinib hydrochloride, or cetuximab [ClinicalTrials.gov identifier NCT01393821]. Available from URL: http://www.clinicaltrials.gov. Accessed 29 Oct 2012.